The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and 10 other professional societies have issued new appropriate use criteria for lymphoscintigraphy in sentinel node mapping and lymphedema/lipedema.
SNMMI hosted two summits recently in Bethesda, MD: the Artificial Intelligence Summit and the Barriers to Patient Access Summit.
Yoshito Kadoya, MD, PhD, assistant professor in the department of cardiovascular medicine at Kyoto Prefectural University of Medicine in Kyoto, Japan, has been named the 2021-2023 Wagner-Torizuka fellow.
SNMMI and 62 organizations, representing more than 1 million healthcare providers, thanked Congress for its past efforts on physician reimbursement and requested the inclusion of specific provisions in future legislation.
Read More
Last week, SNMMI and its partners strongly urged Congress to pass H.R. 1868 to extend the Medicare sequester moratorium through the end of 2021.
Read More
Discussions centered on the need to provide patient access to innovative nuclear diagnostics and the growing role of PET, SPECT, and nuclear medicine in detecting prostate cancer, Parkinson’s, Alzheimer’s, and other life-threatening diseases.
Read More
On February 22, in two letters to the House and Senate, SNMMI and 74 other organizations welcomed the 117th Congress and urged legislators to consider additional policy options in the year ahead to address shortcomings in physician reimbursement.
Read More
On November 6, SNMMI received word regarding Humana’s recent decision to deny coverage for PET/CT on the basis that it is “experimental/investigational” and “not identified as widely used and generally accepted for the proposed uses as reported in nationally recognized peer-reviewed medical literature.” The association objects to this.
Read More